Patents Assigned to McGill University
  • Individualization of therapy with erectile dysfunction agents
    Publication number: 20030073133
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with ED agents.
    Type: Application
    Filed: April 26, 2002
    Publication date: April 17, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Individualization of therapy with immunosuppressants
    Publication number: 20030068273
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with immunosuppressants.
    Type: Application
    Filed: March 14, 2002
    Publication date: April 10, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Peroxisome proliferator-activated receptor alpha and disorders of lipid metabolism
    Patent number: 6544743
    Abstract: The complete genomic structure of the peroxisome proliferator-activated receptor alpha gene is described. Also described are the identification of novel single nucleotide polymorphisms and association with higher plasma LDL-cholesterol and total and LDL-apolipoprotein B concentrations.
    Type: Grant
    Filed: September 14, 2000
    Date of Patent: April 8, 2003
    Assignees: McGill University, Complexe Hospitalier de la Sagamie
    Inventors: Thomas J. Hudson, Marie-Claude Vohl, Carl Brewer, Kenneth Morgan, Daniel Gaudet
  • Compounds and methods for modulating cell adhesion
    Publication number: 20030065136
    Abstract: Cyclic peptides comprising a cadherin cell adhesion recognition sequence HAV, and compositions comprising such cyclic peptides, are provided. Methods for using such peptides for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Application
    Filed: March 22, 2002
    Publication date: April 3, 2003
    Applicant: McGill University
    Inventors: Orest W. Blaschuk, Barbara J. Gour, Riaz Farookhi, Anmar Ali
  • Individualization of therapy with hyperlipidemia agents
    Publication number: 20030053950
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with hyperlipidemia agents.
    Type: Application
    Filed: April 17, 2002
    Publication date: March 20, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Macromers of poly (hydroxyalkanoates)
    Patent number: 6534599
    Abstract: The thermal degradation of the biodegradable bacterial polyesters poly(3-hydroxybutyrate), PHB, and poly(3-hydroxybutyrate-co-3-hydroxyvalerate), PHB/V produces a macromer, especially a 1000-6000 g/mol macromolecule, which contains an unsaturated end group as well as a carboxylic acid end group. The macromers may be polymerized to produce homopolymers and copolymers for different applications in which amphiphilic and biocompatible properties are required, for example, drug delivery systems.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: March 18, 2003
    Assignee: McGill University
    Inventors: Robert H. Marchessault, Sophie Nguyen, Ga-Er Yu
  • Therapeutic and diagnostic uses of protein tyrosine phosphatase TC-PTP
    Patent number: 6534056
    Abstract: Cellular sensitivity to DNA damaging agents and progression through cell cycle is modulated through manipulation of T cell protein tyrosine phosphatase (TC-PTP) activity. Phenotypic characterization of cells lacking TC-PTP demonstrates a defective progression through the cell cycle, and sensitivity to DNA damaging agents. Screening assays are provided for selecting agents that affect the activity of TC-PTP, including assays relating to the interaction of TC-PTP with its substrate, p62dok.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: March 18, 2003
    Assignee: McGill University
    Inventors: Michel L. Tromblay, Maria De Jesus Ibarra Sanchez, Paul Daniel Simoncic
  • DNA assay for the prediction of autoimmune diabetes
    Patent number: 6534272
    Abstract: The present invention relates to a novel DNA assay for the diagnosis and/or prediction of autoimmune diabetes. The present invention relates to a DNA assay for the prediction of autoimmune diabetes in human subjects, which comprises the steps of a) obtaining a DNA sample from the subject and amplifying at least one class III allele of variable number of tandem repeats (VNTR) located upstream of the insulin gene (INS) which is associated with silencing of thymic insulin mRNA expression; and b) subjecting the sample to electrophoresis to identify the silencing class III allele.
    Type: Grant
    Filed: July 23, 2001
    Date of Patent: March 18, 2003
    Assignee: McGill University
    Inventors: Constantin Polychronakos, Petros Vafiadis, Rosemarie Grabs, Houria Ounissi-Benkalha
  • Individualization of therapy with gastroesophageal reflux disease agents
    Publication number: 20030049204
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with GERD agents.
    Type: Application
    Filed: April 24, 2002
    Publication date: March 13, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Methods for detecting human methylenetetrahydrofolate reductase allelic variants
    Patent number: 6528259
    Abstract: Provided herein is a heretofore unknown isolated nucleic acid molecule which encodes human methylenetetrahydrofolate reducatase, along with an amino acid sequence of methylenetetrahydrofolate reductase, and a cDNA probe for human methylenetetrahydrofolate reductase. Also provided are a molecule description of mutations in humans resulting in a phenotype having reduced levels of methylenetetrahydrofolate reductase, and methods of diagnosing methylenetetrahydrofolate reductase deficiency in a human.
    Type: Grant
    Filed: September 13, 2000
    Date of Patent: March 4, 2003
    Assignee: McGill University
    Inventors: Rima Rozen, Philippe Goyette
  • Li-based hydrogen storage composition
    Patent number: 6514478
    Abstract: A hydrogen storage composition has a hydrogenated state and a dehydrogenated state; the hydrogenated state comprises a hydrided composition of lithium and an element M which forms a hydride, for example Be or Mg, an element E which forms a compound or solid solution with lithium, e.g. C, B or Zn, or a mixture thereof; there are thus provided reversible Li-based hydrides of high hydrogen capacity.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: February 4, 2003
    Assignee: McGill University
    Inventors: Alicja Zaluska, Leszek Zaluski, John Olaf Strom-Olsen
  • Timing measurement device using a component-invariant vernier delay line
    Publication number: 20030006750
    Abstract: In recent years, much effort has been placed on improving the performance of timing and jitter measurement devices using Delay Locked Loop (DLL) and Vernier Delay Line (VDL) techniques. However, these approaches require highly matched elements in order to reduce differential non-linearity timing errors. In an attempt to reduce the requirement on element matching, a component-invariant VDL technique is disclosed that enables the measurement device to be synthesized from an RTL description. The present invention is based on a single-stage VDL structure, which is used to mimic the behavior of a complete VDL. Furthermore, as test time is an important consideration during a production test, a method and system is provided that reduces test time at the expense of additional hardware.
    Type: Application
    Filed: March 26, 2002
    Publication date: January 9, 2003
    Applicant: McGill University
    Inventors: Gordon W. Roberts, Antonio H. Chan
  • Screening method for determining individuals at risk of developing diseases associated with different polymorphic forms of wildtype P53
    Patent number: 6489105
    Abstract: The present invention relates to a screening method to identify individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53; which comprises the steps of: a) obtaining a biological sample from said patients; and b) determining the presence of p53pro or p53arg wildtype alleles in said sample; wherein the allele pattern of patients selected from the group consisting of p53pro/p53pro, p53arg/p53arg and p53pro/p53arg are indicative of a risk factor for developing disease associated with different polymorphic forms of wildtype p53. Notably, individuals who are p53arg/arg are at greater risk of developing pathologies associated with human papillomavirus infections, including cervical cancer.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: December 3, 2002
    Assignees: McGill University, Imperial Cancer Research Technology, International Center for Genetic Engineering and Biotechnology
    Inventors: Greg J. Matlashewski, Lawrence Banks, Alan Storey
  • Oligonucleotides having alkylphosphonate linkages and methods for their preparation
    Patent number: 6486313
    Abstract: The present invention provides alkylphosphonate dimers and oligonucleotides prepared therefrom. The invention further provides novel methods for the preparation of these alkylphosphonate dimers. Methods for the preparation of substantially diastereomerically pure alkylphosphonate dimers are also provided.
    Type: Grant
    Filed: February 18, 1999
    Date of Patent: November 26, 2002
    Assignees: ISIS Pharmaceuticals, Inc., McGill University
    Inventors: Muthiah Manoharan, George Just, Andrei Guzaev, Arlène Roland, Jianchao Wang, Michael E. Jung
  • Single actuator per leg robotic hexapod
    Patent number: 6481513
    Abstract: A mobile robot comprising a body and at least six compliant legs each having only one actuator. The compliant legs are mounted to the body for movement relative thereto in a single degree of freedom. A controller is operably coupled to the actuator of each compliant leg, the controller selectively actuates the actuators to drive the compliant legs in an alternating tripod gait.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: November 19, 2002
    Assignees: McGill University, The Regents of the University of Michigan
    Inventors: Martin Buehler, Daniel E. Koditschek, Uluc Saranli
  • Biosensor device and method
    Patent number: 6478939
    Abstract: A biosensor apparatus for detecting a binding event between a ligand and receptor. The apparatus includes a biosensor surface and surface-bound two-subunit heterodimer complexes composed of first and second, preferably oppositely charged peptides that together form an &agr;-helical coiled-coil heterodimer. The first peptide is attached to the biosensor surface, and the second peptide carries the ligand, accessible for binding by a ligand-binding agent. Binding of anti-ligand binding agent to the surface-bound ligand is detected by a suitable detector. A ligand-specific biosensor surface can be readily prepared from a universal template containing the first charged peptide, by addition of a selected ligand attached to the second peptide.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: November 12, 2002
    Assignees: Pence, Inc., McGill University
    Inventors: R. Bruce Lennox, Robert S. Hodges, Randall T. Irvin
  • Preparation of phosphorothioate oligomers
    Patent number: 6476216
    Abstract: The present invention is directed to methods for solid phase nucleotide synthesis utilizing substituted imidazole catalysts.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: November 5, 2002
    Assignee: McGill University
    Inventors: George Just, Zhili Xin, Eric Marsault, Yi Jin, Jianchao Wang
  • Very low density lipoprotein receptor polymorphisms and uses therefor
    Publication number: 20020155446
    Abstract: Polymorphic nucleic acid molecules encoding the very low density lipoprotein receptor are described, as well as gene products encoded by these nucleic acid molecules. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also described, along with methods of use therefor.
    Type: Application
    Filed: March 8, 2001
    Publication date: October 24, 2002
    Applicant: McGill University
    Inventors: James Engert, Marie-Claude Vohl, Carl Brewer, Kenneth Morgan, Daniel Gaudet, Thomas J. Hudson
  • Diblock copolymer and use thereof in a micellar drug delivery system
    Patent number: 6469132
    Abstract: The present invention relates to diblock copolymers and more particularly to polycaprolactone-b-polyethylene oxide (PCL-b-PEO) diblock copolymers used in micellar systems, for delivering a biologically active agent to a site. There is provided a diblock copolymer compound comprising a hydrophilic block and a hydrophobic block, the hydrophilic block comprising a polyethylene oxide (PEO) polymer, the hydrophobic block comprising a polycaprolactone (PCL) polymer, the PCL polymer comprising a number of caprolactone monomers selected from 5 to 150, the PEO polymer comprising a number of ethylene oxide monomers selected from 30 to 100. The diblock copolymer compound of the present invention may be used to form a micellar delivery system for delivering biologically active agents such as lipophilic drugs to sites such as the central nervous system.
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: October 22, 2002
    Assignee: McGill University
    Inventors: Adi Eisenberg, Dusica Maysinger, Christine Allen
  • Compounds and methods for modulating cell adhesion
    Publication number: 20020151475
    Abstract: Cyclic peptides and compositions comprising such cyclic peptides are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Application
    Filed: December 4, 2001
    Publication date: October 17, 2002
    Applicant: McGill University
    Inventors: Orest W. Blaschuk, Barbara J. Gour